PUBLISHER: TechNavio | PRODUCT CODE: 1693000
PUBLISHER: TechNavio | PRODUCT CODE: 1693000
The cardiovascular therapeutics market is forecasted to grow by USD 25.32 billion during 2024-2029, accelerating at a CAGR of 4.6% during the forecast period. The report on the cardiovascular therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing risk factors for cardiovascular diseases, availability of advanced diagnostic methods, and rising prevalence of hypercholesterolemia.
Market Scope | |
---|---|
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 4.3% |
CAGR | 4.6% |
Incremental Value | $25.32 bn |
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's cardiovascular therapeutics market is segmented as below:
By Distribution Channel
By Type
By Route Of Administration
By Geographical Landscape
This study identifies the advent of novel oral anticoagulants (NOACs) as one of the prime reasons driving the cardiovascular therapeutics market growth during the next few years. Also, identification of new pathogenic targets related to cardiovascular diseases and strong incidence of coronary heart disease (CHD) worldwide will lead to sizable demand in the market.
The report on the cardiovascular therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cardiovascular therapeutics market vendors that include Abbott Laboratories, Acutus Medical Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., DR Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline PLC, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the cardiovascular therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: